Effect of Atorvastatin in treatment of COVID-19 infectio

Phase 3

Conditions: COVID-19 infection.
COVID-19 has been confirmed by laboratory testing
U07.1

Registration Number: IRCT20200413047062N1

Lead Sponsor: Islamic Azad University

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 76

Inclusion Criteria

Patients age over 18 years
Hospitalized with diagnosis of COVID-19 infection

Exclusion Criteria

Pregnancy
Lactation
History of hypersensitivity reaction to atorvastatin,
Liver dysfunction (Liver enzymes > 3 ULN or bilirubin >2 ULN or history of liver failure)
Renal failure (eGFR < 30ml/min),
History of major side effects with statins (such as liver toxicity, rhabdomyolysis)
Patients are receiving other drugs which have major interaction (such as Gemfibrozil, cyclosporine, amiodarone, itraconazole, variconazole, clarithromycin)
LDL Level below than 40 mg/dl
Involvement in another clinical study

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time to clinical improvement (TTIC). Timepoint: Daily. Method of measurement: Based on clinical findings such as fever, respiratory rate, percentage of oxygen saturation, cough.;Duration of hospitalization. Timepoint: End of the treatment. Method of measurement: Patient's record.;Adverse effects. Timepoint: Daily. Method of measurement: Interview and patient's record.;Clinical outcome (cure or death). Timepoint: End of the treatment. Method of measurement: Patient's record.

Secondary Outcome Measures

Name	Time	Method
eed for ICU admission. Timepoint: Daily. Method of measurement: Patient's record.;Need for Mechanical ventilation. Timepoint: Daily. Method of measurement: Interview and patient's record.;Change in radiologic findings. Timepoint: End of the treatment. Method of measurement: Patient's record.;The change in inflammatory markers. Timepoint: daily. Method of measurement: Patient's record.